Key insights
- Eli Lilly launched its Alzheimer's drug Lormalzi (Donanemab) in India, signaling its strategic focus on emerging markets. While the immediate US market impact is limited, this move indicates Lilly's global expansion and potential revenue diversification, which could be viewed positively by investors in the long term.
Investing.com -- Eli Lilly launched its Alzheimer’s drug Lormalzi in India on Wednesday, with a 350 mg vial priced at 91,688 rupees ($957), the company told Reuters.
The drug, also known as Donanemab, is expected to become commercially available later this month. The therapy will be administered as an intravenous infusion once every four weeks to remove amyloid plaques in the brain associated with Alzheimer’s progression.
Lormalzi has received marketing authorization from India’s Central Drugs Standard Control Organization for patients with mild cognitive impairment or mild dementia stages of Alzheimer’s. The drug was approved in the U.S. last year under the brand name Kisunla.
A Lilly executive said earlier this year that India would play a bigger role in the company’s global strategy, including as a manufacturing and export hub. Winselow Tucker, president and general manager of Eli Lilly and Company (India), said in February the drugmaker planned to bring additional products to India.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.